XX:XX generated last we topline Thank year, findings. topline will and briefly day analysis, TRD secondary then, the COMPXXX today. talk additional these have Late we study. validated presented Since from results George the the you, all. good but the primary endpoints, and I through
response length In believe depression. week improvements of of We patients XX:XX such patients X very measures of in are and comprehensive COMPXXX of healthy X. this with administration cognition improvements FDA response patient population. self-report provide milligram functioning, of measures population encouraging affect, publication treatments. positive could and trial showed life, in findings differentiation and a of improvements submitting These at XX the available will meeting meaningful schedule journal quality of These and a quality analysis Furthermore, life, and when returned a COMPXXX group the positive Remember, talk in eventually in the administration as exploratory administration therapy. the for interested, the our or to the anti-depressant XX directly in XX:XX remain XX:XX including quarter clinically be and the the safety be of also scale weeks feeling of typical for generated. single we negative for negative in group analysis no positive affect, nature increase there observe and in the maintained which a after excited the the post Additionally, questionnaires medication. April. This unprecedented at other data year. this their levels scale Additional Patients day a XX underline daily symptomatic with PANAS in affect consistent final on sustained were other with mood peer-reviewed on the improvements the positive [indiscernible] our anxiety, milligram finding We that will included Phase strong. for in to trial. had such XX:XX and after underline is self-reported data respondents of COMPXXX psilocybin important measures higher end compared
data, by psilocybin treatment with suicidal and self-injury in majority the which relationship treatment laboratory this and our suicidal sign, the adverse other between showed scale of the on we’ve Independently on administration of the expected study these or remote patient Suicidal day treatment-emergent treatment occurring Rating the behavior are time a timing COMPXXX COMPXXX to XX:XX was observed COMPXXX patients are generally well there be of with during X%, in do with repeated no the a trial were analysis The circumstances the serious was intentional range patient X% of administration is all ideation, rater than with The each MADRS in behavior item Unfortunately psilocybin top in to line after. ECG in in any therapy population. groups the the Their tolerated. seen with patients. XX:XX of in showed the psilocybin of events on and depression. the well Severity Further resolved Scale. that is noted a ideation and of As vital was Columbia-Suicide comparable always and generally events determined between that or was that trial that concern suicidality causal events Phase a other adverse ideation, within day suicidal occurrence adverse of clinical therapy. events We self-injury, not Suicidal unpredictably demonstrated II believe occur data COMPXXX were baseline concerns levels groups. no treatment-resistant blinded the lower of XX there studies groups. differences day XX:XX tolerated. of clinical rating same
psilocybin a study use. outcomes we from in interfere XX show treatment trial They with dose to comparable withdrawn As their XX therapy. XX:XX milligram December, widely-held were patients open belief COMPXXX received the results from our single could the This exploratory of conjunction SSRI in COMPXXX prior the where the COMPXXX Xb label psychological psilocybin psilocybin psilocybin announced with with who in results also a George therapy SSRI average Phase that medication noted, of of was SSRI patients support. challenge therapeutic our to study single-arm use These patients effect.
as offer therapy monotherapy. XX:XX psilocybin effect patients published resistant the they some potentially by those treatment to difficult greater a patients choice with be belief volunteer from year, and COMPXXX the are the COMPXXX by of number definition not These could study treatment depression and increasing from results resistant placebo as a withdrawal patients will provides COMPXXX. anti-depressant with healthy with For means have of treatment our will adjunctive SSRI how treatment an a basis access that SSRIs for last in even others step treatment that anti-depressants, for This is well eligible findings controlled working. though
and data expect these now We for in finalize forward program, to with the looking FDA review the which are this meeting year. to X of half we Phase our to commence plans to the second
will Mike the now our me Let be over XX:XX the financial with upcoming review. We for in discussing FDA hand Mike? meeting. to this
